{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:07:14Z","timestamp":1790690834786,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01CA266298"],"award-info":[{"award-number":["R01CA266298"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["JNJ-64619178"],"award-info":[{"award-number":["JNJ-64619178"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001286","name":"Pan-Massachusetts Challenge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100249","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T22:27:07Z","timestamp":1778970427000},"page":"100249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death"],"prefix":"10.1016","volume":"3","author":[{"given":"Fen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-6243","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-1943","authenticated-orcid":false,"given":"Christine E.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3330-2369","authenticated-orcid":false,"given":"Liam","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson","family":"Ung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J. F.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2003","authenticated-orcid":false,"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2026.100249_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2008.12.013","article-title":"Protein arginine methylation in mammals: who, what, and why","volume":"33","author":"Bedford","year":"2009","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.bneo.2026.100249_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine methylation: the coming of age","volume":"65","author":"Blanc","year":"2017","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.bneo.2026.100249_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.gendis.2019.06.002","article-title":"PRMT5 in gene regulation and hematologic malignancies","volume":"6","author":"Zhu","year":"2019","journal-title":"Genes Dis"},{"issue":"24","key":"10.1016\/j.bneo.2026.100249_bib4","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1128\/MCB.21.24.8289-8300.2001","article-title":"The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins","volume":"21","author":"Friesen","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"7558","key":"10.1016\/j.bneo.2026.100249_bib5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature14351","article-title":"MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis","volume":"523","author":"Koh","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bneo.2026.100249_bib6","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/s41375-019-0489-6","article-title":"PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K\/AKT in lymphoma cells","volume":"33","author":"Zhu","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2026.100249_bib7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100249_bib8","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1038\/s41598-018-28002-y","article-title":"Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing","volume":"8","author":"Gerhart","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.bneo.2026.100249_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-023-00799-6","article-title":"Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations","volume":"13","author":"Che","year":"2023","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.bneo.2026.100249_bib10","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100249_bib11","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1182\/blood-2021-146987","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes","volume":"138","author":"Haque","year":"2021","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bneo.2026.100249_bib12","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.bneo.2026.100249_bib13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100249_bib14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","article-title":"The rise of apoptosis: targeting apoptosis in hematologic malignancies","volume":"132","author":"Valentin","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2026.100249_bib15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1515\/hsz-2016-0107","article-title":"iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry","volume":"397","author":"Ryan","year":"2016","journal-title":"Biol Chem"},{"issue":"10","key":"10.1016\/j.bneo.2026.100249_bib16","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.3390\/cancers15102752","article-title":"The role of TRAIL in apoptosis and immunosurveillance in cancer","volume":"15","author":"Pimentel","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bneo.2026.100249_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bneo.2026.100249_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"issue":"20","key":"10.1016\/j.bneo.2026.100249_bib19","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1158\/1078-0432.CCR-07-0950","article-title":"Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers","volume":"13","author":"Plummer","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bneo.2026.100249_bib20","first-page":"13","article-title":"Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)","volume":"25","author":"Forero-Torres","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"issue":"17","key":"10.1016\/j.bneo.2026.100249_bib21","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.bneo.2026.100249_bib22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/sj.bjc.6605507","article-title":"Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer","volume":"102","author":"Trarbach","year":"2010","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.bneo.2026.100249_bib23","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-10-0631","article-title":"A first-in-human study of conatumumab in adult patients with advanced solid tumors","volume":"16","author":"Herbst","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bneo.2026.100249_bib24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bneo.2026.100249_bib25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"7","key":"10.1016\/j.bneo.2026.100249_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"9","key":"10.1016\/j.bneo.2026.100249_bib27","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.celrep.2019.02.001","article-title":"PRMT5 modulates splicing for genome integrity and preserves proteostasis of hematopoietic stem cells","volume":"26","author":"Tan","year":"2019","journal-title":"Cell Rep"},{"issue":"17","key":"10.1016\/j.bneo.2026.100249_bib28","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1101\/gad.219899.113","article-title":"Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery","volume":"27","author":"Bezzi","year":"2013","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.bneo.2026.100249_bib29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.2023.283245","article-title":"Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax","volume":"109","author":"Zhu","year":"2024","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.bneo.2026.100249_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170169","article-title":"Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies","volume":"133","author":"Chong","year":"2023","journal-title":"J Clin Invest"},{"issue":"95","key":"10.1016\/j.bneo.2026.100249_bib31","doi-asserted-by":"crossref","first-page":"36804","DOI":"10.18632\/oncotarget.26407","article-title":"Tubulin couples death receptor 5 to regulate apoptosis","volume":"9","author":"Twomey","year":"2018","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.bneo.2026.100249_bib32","doi-asserted-by":"crossref","first-page":"e3069","DOI":"10.1038\/cddis.2017.466","article-title":"Secretory stressors induce intracellular death receptor accumulation to control apoptosis","volume":"8","author":"van Raam","year":"2017","journal-title":"Cell Death Dis"},{"issue":"6","key":"10.1016\/j.bneo.2026.100249_bib33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.devcel.2020.01.031","article-title":"TRAIL receptors serve as stress-associated molecular patterns to promote ER-stress-induced inflammation","volume":"52","author":"Sullivan","year":"2020","journal-title":"Dev Cell"},{"issue":"9","key":"10.1016\/j.bneo.2026.100249_bib34","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/cr.2010.56","article-title":"PRMT5 regulates Golgi apparatus structure through methylation of the golgin GM130","volume":"20","author":"Zhou","year":"2010","journal-title":"Cell Res"},{"issue":"4","key":"10.1016\/j.bneo.2026.100249_bib35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.bneo.2026.100249_bib36","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1182\/bloodadvances.2023009906","article-title":"PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma","volume":"7","author":"Brown-Burke","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.bneo.2026.100249_bib37","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1158\/0008-5472.CAN-20-2178","article-title":"Hexavalent TRAIL fusion protein eftozanermin alfa optimally clusters apoptosis-inducing TRAIL receptors to induce on-target antitumor activity in solid tumors","volume":"81","author":"Phillips","year":"2021","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.bneo.2026.100249_bib38","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-23-0974","article-title":"Preclinical characterization and phase I trial results of INBRX-109, a third-generation, recombinant, humanized, death receptor 5 agonist antibody, in chondrosarcoma","volume":"29","author":"Subbiah","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bneo.2026.100249_bib40","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s10637-022-01247-1","article-title":"Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study","volume":"40","author":"LoRusso","year":"2022","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.bneo.2026.100249_bib42","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.4049\/jimmunol.163.4.1906","article-title":"Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells","volume":"163","author":"Kayagaki","year":"1999","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100249_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-7613(02)00502-2","article-title":"Nature\u2019s TRAIL--on a path to cancer immunotherapy","volume":"18","author":"Smyth","year":"2003","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.bneo.2026.100249_bib44","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00262-019-02368-y","article-title":"Interferon beta increases NK cell cytotoxicity against tumor cells in patients with nasopharyngeal carcinoma via tumor necrosis factor apoptosis-inducing ligand","volume":"68","author":"Makowska","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"10.1016\/j.bneo.2026.100249_bib45","article-title":"Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies","volume":"3","author":"Ten Hacken","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.bneo.2026.100249_bib46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41467-018-08150-5","article-title":"Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators","volume":"10","author":"Aird","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bneo.2026.100249_bib47","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bneo.2026.100249_bib48","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0092-8674(00)81382-3","article-title":"Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)","volume":"87","author":"Zha","year":"1996","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bneo.2026.100249_bib49","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1158\/0008-5472.CAN-11-4106","article-title":"Mcl-1 phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells","volume":"72","author":"Mazumder","year":"2012","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.bneo.2026.100249_bib50","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1182\/blood-2014-03-563296","article-title":"Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56\u03b4 stabilizes its antiapoptotic activity","volume":"124","author":"Low","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2026.100249_bib51","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201745235","article-title":"Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance","volume":"19","author":"Kale","year":"2018","journal-title":"EMBO Rep"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:17:28Z","timestamp":1790687848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000609"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100249","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100249"}}